About Us

About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ImmunoPrecise Advances AI Discovered and Developed Universal Dengue Vaccine Initiative: Moves into Preclinical Antibody Generation

By: via Business Wire

Manufacturing of validated dengue epitope underway; proprietary immunization studies in rabbit model to assess monoclonal antibody (mAb) responses.

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a biotherapeutics company delivering advanced solutions in biologics and drug discovery today announced the next milestone in its universal dengue vaccine program. Building on its June announcements confirming the discovery and validation of a uniquely conserved dengue epitope using its LENSai™ platform powered by patented HYFT® technology, the Company has updated that they are now advancing to pre-clinical manufacturing for in vivo (in animal) testing and virus neutralization analysis.

The manufactured product will be used in proprietary immunization protocols at IPA’s Canadian facility. These studies, conducted in a rabbit model, are designed to evaluate whether the vaccine candidate elicits robust monoclonal antibody (mAb) responses—a crucial step toward translational development.

“This is the natural next step in our journey from AI discovery to real-world validation,” said Dr. Jennifer Bath, CEO of ImmunoPrecise. “We’ve shown that HYFT technology can identify vaccine targets that others miss — unique targets that are conserved, specific, and immunologically relevant. Now we’re now moving into manufacturing and live immunization studies, where the question becomes: can this target elicit a powerful and protective antibody response? This is where discovery turns into translational reality, with dengue as the first example of what our platform can achieve across infectious diseases.”

The science behind the step:

  • AI Discovery → Manufacturing: HYFT-guided analysis revealed a discontiguous dengue epitope conserved across all four virus serotypes.
  • Validated Safety & Immunogenicity: In silico screens confirmed immune activation potential (B- and T-cell responses), structural stability, and comprehensive safety against host proteomes.
  • Now Entering Immunization Studies: The product is being synthesized and will be used in rabbit models to assess whether it elicits specific monoclonal antibodies — an essential proof point for vaccine development.

A platform approach, not just a vaccine:

This progression highlights IPA’s end-to-end advantage: combining AI-native discovery with in-house wet-lab validation. With regulators like the U.S. FDA encouraging predictive, human-relevant approaches that reduce reliance on animal testing, ImmunoPrecise’s in silico-to-in vivo workflow represents a forward-looking model for next-generation vaccine R&D.

By applying the same methodology across pathogens, IPA is positioning its LENSai/HYFT platform as a versatile discovery engine — not only for dengue, but also for other infectious diseases and immuno-oncology targets.

About ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) is a biotherapeutics company focused on the discovery and development of next-generation biologics. The Company combines scientific expertise with proprietary technologies—such as its LENSai™ platform—to accelerate drug discovery and improve decision-making across complex biological systems. IPA supports global partners in advancing novel therapeutics, diagnostics, and translational research. For more information, visit www.ipatherapeutics.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. Forward-looking statements are often identified by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “potential,” or similar expressions, or by statements that certain actions, events, or results “may,�� “will,” “could,” or “might” occur or be achieved. These include, but are not limited to, statements regarding the Company’s advancement of its universal dengue vaccine initiative, the anticipated benefits of its proprietary HYFT® and LENSai™ platforms, the potential for its vaccine candidate to generate protective monoclonal antibody responses, and the broader applicability of its AI-native discovery platforms to infectious diseases and immuno-oncology.

Forward-looking statements are based on management’s current expectations, assumptions, and projections about future events and Company performance. Actual results could differ materially from those expressed or implied due to factors beyond the Company’s control, including: risks inherent in preclinical studies and vaccine development; uncertainties in manufacturing, immunization, and virus neutralization testing; execution risks related to AI-driven discovery and translational validation; the pace and accuracy of scientific and technological innovation; competitive dynamics in biologics and vaccine R&D; customer and partner adoption rates; and shifts in economic, market, or regulatory conditions.

Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. Additional information about these and other risks and uncertainties is set out in the Company’s Annual Report on Form 20-F, as amended, for the fiscal year ended April 30, 2025, available on the Company’s SEDAR+ profile at www.sedarplus.ca and EDGAR profile at www.sec.gov/edgar. If any of these risks materialize, the Company’s actual results, performance, or achievements could vary significantly from those currently anticipated.

Readers are cautioned not to place undue reliance on forward-looking statements. Except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise.

This is where discovery turns into translational reality, with dengue as the first example of what our platform can achieve across infectious diseases

Contacts

More News

View More
Advance Auto Parts is A Great Risk/Reward Play If EPS Delivers
Via MarketBeat
Topics Economy World Trade
Tickers AAP
3 Small Caps That Insiders Are Buying
Via MarketBeat
Topics Artificial Intelligence Retirement
Tickers AAOI NTWK THRY
3 Big Short Interest Names with Bullish Setups
Via MarketBeat
Topics Artificial Intelligence
Tickers ASX:PDN DLO HIMS TEM
Why Datavault May be the Penny AI Stock Investors Have Waited For
Via MarketBeat
Topics Artificial Intelligence
Tickers DVLT IBM
These 3 Stocks Boosting Buybacks Have Rallying Potential
Via MarketBeat
Tickers CMG TKO WDAY
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.